信迪利单抗联合化疗在中晚期非小细胞肺癌治疗中的效果

Effect of Sintilimab Combined with Chemotherapy in the Treatment of Intermediate and Advanced Non-small Cell Lung Cancer

目的:探讨信迪利单抗联合化疗在中晚期非小细胞肺癌(NSCLC)患者中的疗效。方法:选取2021年1月—2022年12月泰州市第四人民医院收治的中晚期NSCLC患者30例为研究对象,采用信封法随机分为研究组和对照组,各15例。对照组采用常规化疗,研究组在对照组基础上联合信迪利单抗治疗。比较两组近期疗效、肿瘤标志物、不良反应发生率、生活质量。结果:研究组客观缓解率、疾病控制率高于对照组,差异有统计学意义(P<0.05);研究组治疗后肿瘤标志物水平低于对照组,差异有统计学意义(P<0.001);两组不良反应发生率比较,差异无统计学意义(P>0.05);治疗后,两组世界卫生组织生存质量测定量表评分均高于治疗前,研究组高于对照组,差异有统计学意义(P<0.05)。结论:信利迪单抗联合化疗能够提高中晚期NSCLC患者近期疗效,降低肿瘤标志物水平,改善生活质量,同时不会增加不良反应。

Objective:To explore the efficacy of sintilimab combined with chemotherapy in patients with intermediate and advanced non-small cell lung cancer(NSCLC).Methods:A total of 30 patients with intermediate and advanced NSCLC were selected as the study objects in the Taizhou Fourth People's Hospital from January 2021 to December 2022,and were randomly divided into study group and control group by envelope method,with 15 cases in each group.The control group received conventional chemotherapy,and the study group was treated with sintilimab on the basis of the control group.The short-term efficacy,tumor markers,incidence of adverse reactions and quality of life were compared between the two groups.Results:The objective remission rate and disease control rate of the study group were higher than those of the control group,and the difference was statistically significant(P<0.05);after treatment,the level of tumor markers in the study group was lower than that in the control group,and the difference was statistically significant(P<0.001);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05);after treatment,the scores of the World Health Organization Quality of Life Scale in both groups were higher than before treatment,and the study group was higher than the control group,the difference was statistically significant(P<0.05).Conclusion:Sintilimab combined with chemotherapy can improve the short-term efficacy of patients with intermediate and advanced NSCLC,reduce tumor marker levels,and improve quality of life without increasing adverse reactions.